Axovant Sciences (NASDAQ:AXON)’s share price was down 9.4% during mid-day trading on Wednesday . The stock traded as low as $1.13 and last traded at $1.28. Approximately 18,935 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 1,228,246 shares. The stock had previously closed at $1.17.
Several equities analysts recently issued reports on AXON shares. ValuEngine downgraded Axovant Sciences from a “sell” rating to a “strong sell” rating in a research report on Monday, April 2nd. Cowen downgraded Axovant Sciences from an “outperform” rating to a “market perform” rating in a research report on Friday, January 12th. Zacks Investment Research raised Axovant Sciences from a “hold” rating to a “buy” rating and set a $2.25 target price on the stock in a research report on Wednesday, January 31st. Chardan Capital raised Axovant Sciences from a “sell” rating to a “neutral” rating and set a $2.50 target price on the stock in a research report on Wednesday, January 10th. Finally, Oppenheimer reissued a “hold” rating on shares of Axovant Sciences in a research report on Tuesday, February 13th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the company. Axovant Sciences currently has a consensus rating of “Hold” and a consensus price target of $13.61.
The company has a debt-to-equity ratio of 0.45, a quick ratio of 4.58 and a current ratio of 4.58. The firm has a market cap of $150.90 million, a P/E ratio of -0.73 and a beta of -0.37.
In other Axovant Sciences news, Director George Bickerstaff purchased 25,000 shares of the stock in a transaction on Tuesday, February 27th. The shares were bought at an average cost of $1.50 per share, with a total value of $37,500.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 72.40% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of AXON. Cubist Systematic Strategies LLC purchased a new stake in shares of Axovant Sciences during the 3rd quarter worth about $117,000. Virtus Fund Advisers LLC purchased a new stake in shares of Axovant Sciences during the 4th quarter worth about $349,000. Wells Fargo & Company MN boosted its stake in shares of Axovant Sciences by 135.6% during the 3rd quarter. Wells Fargo & Company MN now owns 53,695 shares of the biotechnology company’s stock worth $369,000 after acquiring an additional 30,905 shares in the last quarter. Hikari Power Ltd purchased a new stake in shares of Axovant Sciences during the 4th quarter worth about $377,000. Finally, Alliancebernstein L.P. boosted its stake in shares of Axovant Sciences by 108.8% during the 4th quarter. Alliancebernstein L.P. now owns 108,600 shares of the biotechnology company’s stock worth $572,000 after acquiring an additional 56,600 shares in the last quarter. 93.01% of the stock is currently owned by institutional investors.
Axovant Sciences Company Profile
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for the treatment of dementia and related neurological disorders in the United States and Europe. Its lead product candidate, intepirdine, a selective 5-HT6 receptor antagonist, which is in Phase III clinical trial for the treatment of Alzheimer's disease; in Phase IIb clinical trial for treating dementia with Lewy bodies (DLB); and in Phase II clinical trial for treating cait and balance in Alzheimer's disease, DLB, and Parkinson's disease dementia.
Receive News & Ratings for Axovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.